Novel eye test may help detect Alzheimer's

Image
Press Trust of India Los Angeles
Last Updated : Aug 23 2017 | 6:28 PM IST
Scientists have developed a noninvasive eye imaging test that could allow early detection of Alzheimer's disease.
The technology, developed by Cedars-Sinai Medical Center and NeuroVision company in the US, scans the retina using techniques that can identify beta-amyloid protein deposits - hallmarks of Alzheimer's - that mirror those in the brain.
Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.
"This is the first study demonstrating the potential to image and quantify retinal findings related to beta-amyloid plaques noninvasively in living patients using a retinal scan with high resolution," said Maya Koronyo-Hamaoui, a research scientist at Cedars-Sinai.
"Findings from this study strongly suggest that retinal imaging can serve as a surrogate biomarker to investigate and monitor Alzheimer's disease," said Koronyo-Hamaoui.
As a developmental outgrowth of the central nervous system that shares many of the brain's characteristics, the retina may offer a unique opportunity to easily and conveniently detect and monitor Alzheimer's disease, said Keith L Black, from Cedars-Sinai.
"We know that Alzheimer's begins as many as 10 or 20 years before cognitive decline becomes evident, and we believe that potential treatments may be more effective if they can be started early in the process.
"Therefore, screening and early detection may be crucial to our efforts to turn the tide against the growing threat of this devastating disease," said Black.
The researchers carried a 16-patient clinical trial to demonstrate the feasibility of identifying beta-amyloid in the eye using autofluorescence imaging.
They found a 4.7-fold increase in retinal plaque burden in patients with Alzheimer's, compared to controls.
With the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large- scale identification of the at-risk population and monitoring of Alzheimer's, the researchers said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 23 2017 | 6:28 PM IST

Next Story